Semler Scientific® Announces Additional Bitcoin Purchases 
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively -...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema...
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the...
Healthcare Triangle, Inc. to Participate at the 2024 MUSE Executive Institute
PLEASANTON, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader...
Axial Therapeutics to Present at Upcoming Conferences
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted,...
Spero Therapeutics Provides Corporate Update and 2024 Outlook
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients...
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today...
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to...
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
Lykos Therapeutics, formerly known as MAPS PBC, announced the close of Series A financing to support regulatory and pre-launch activities...
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Smart for Life Announces Completion of Audit for Pending Acquisition
Acquisition Expected to Contribute More than $8 Million of Annualized Revenue and Positive Net IncomeMIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE)...
Stryker to announce financial results for its fourth quarter and full year 2023
Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter...
First ReWalk Personal Exoskeleton Claim Paid by Medicare
ReWalk Personal Exoskeleton covered as a medically necessary device for an eligible Medicare beneficiary with spinal cord injuryMARLBOROUGH, Mass. and...
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement
MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests...
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel...
CervoMed to Participate in the Emerging Growth Conference 66
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Compass Therapeutics Provides Corporate Update
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on...